Subcutaneous Immunoglobulin Market Segments, Leading Player, Application & Forecast Analysis

According to Transparency Market Research’s latest report on the global subcutaneous immunoglobulin market for the historical period 2017–2018 and forecast period 2019–2027, Rise in prevalence of autoimmune disorders, Increase in global geriatric population, Growing usage in off-label indications are projected to drive the global subcutaneous immunoglobulin market during the forecast period
According to the report, the global subcutaneous immunoglobulin market was valued at US$ 4.0 Bn in 2018 and is anticipated to expand at a CAGR of 13.1% from 2019 to 2027

To know the scope of our report Get a Sample on Subcutaneous Immunoglobulin Market

The global subcutaneous immunoglobulin market continues to expand at a high growth rate due to increasing prevalence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. For instance, According to the Immune Deficiency Foundation (IDF), in 2018, approximately 1 people per 4,000 in the U.S. suffer from primary immunodeficiency and there are over 5 million undiagnosed cases in the U.S. alone.
Prevalence of several diseases such as cancer, diabetes, and neurological disorders is rising due to rapidly increasing geriatric population. The geriatric population is more vulnerable to diseases due to poor immunity.
According to the World Health Organization, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050 as against 900 million in 2015. Countries such as India, China, Thailand, and South Korea are also expected to have large geriatric populations in the shortest span of time in the near future.

Get a glimpse of the in-depth analysis through our Report Brochure

The steady increase in the use of immunoglobulin for treatment of off-label indications is expected to drive the market during the forecast period. Common off-label indications treated with intravenous immunoglobulin are Guillain-Barre syndrome, multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis, among others
Technological improvements in the production and purification methods of intravenous and subcutaneous immunoglobulin (SCIG) have made these safer and free from protein, viral, or any other contaminants. This has increased clinician preference for usage of IVIG and SCIG. This in turn is expected to boost demand for subcutaneous immunoglobulin.

Cost of plasma collection and manufacturing processes is high as compared to materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood derived component, highly sophisticated collection, purification, and storage methods are required for subcutaneous immunoglobulin (SCIG) products.
Due to fewer market players and the time gap between plasma collection and getting the product in the market, SCIG production becomes a tedious and time-consuming process, if not managed properly can hamper the subcutaneous immunoglobulin (SCIG) market during the forecast period.

This report profiles major players in the global subcutaneous immunoglobulin market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global subcutaneous immunoglobulin market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global subcutaneous immunoglobulin market are

Expanding operations in future? To get the perfect launch ask for a custom report